So we wind up paying twice — once to invent the drug and again when it comes to market,” he said. Soaring drug costs have led to a spike in US spending on cancer medicine, which has doubled since 2013. Photograph: By 2022, US costs are forecast to double yet again, while the global market for cancer therapeutic medicines is expected to reach $200bn.
Soaring drug costs have led to a spike in US spending on cancer medicine, which has doubled since 2013. Photograph: By 2022, US costs are forecast to double yet again, while the global market for cancer therapeutic medicines is expected to reach $200bn.